Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Anticopper drugs that have been developed to treat Wilson's disease, a disease of copper toxicity, include tetrathiomolybdate, zinc, penicillamine, and trientine. Lowering copper levels by a modest amount in non-Wilson's patients with tetrathiomolybdate inhibits angiogenesis, fibrosis and inflammation while avoiding clinical copper deficiency. Through this mechanism tetrathiomolybdate has proven effective in numerous animal models of cancer, retinopathy, fibrosis, and inflammation. Penicillamine has efficacy in rheumatoid arthritis and trientine has efficacy in diabetic neuropathy and diabetic heart disease. If clinical studies support the animal work, anticopper therapy holds promise for therapy of cancer, fibrotic disease and inflammatory and autoimmune diseases.
Brewer
George J
GJ
Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109-0534, USA. brewergj@umich.edu
D000818:Animals; D003300:Copper / Q000037:antagonists & inhibitors*; D005355:Fibrosis; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008982:Molybdenum / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D010396:Penicillamine / Q000627:therapeutic use; D014266:Trientine / Q000627:therapeutic use
D003300:Copper; D008982:Molybdenum; C020809:tetrathiomolybdate; D010396:Penicillamine; D014266:Trientine